Audeo Files for $60M IPO for Late-Stage Cancer Products
By Catherine Shaffer
Tuesday, July 10, 2012
Audeo Oncology Inc. filed for a $60 million initial public offering (IPO) to support clinical trials of its products based on hyaluronic acid chemotransport technology (HyACT) for cancer. The HyACT platform is designed to boost the effectiveness of cancer drugs without increasing toxicity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.